The use of platelet‐rich plasma in treatment of olfactory dysfunction: A pilot study

• Published in: Laryngoscope investigative otolaryngology Vol. 5; no. 2; pp. 187 - 193
• Main Authors: Yan, Carol H., Mundy, David C., Patel, Zara M.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.04.2020; Wiley
• Subjects: Allergy, Rhinology, and Immunology; Blood platelets; Endoscopy; Growth factors; hyposmia; Identification; olfaction; Olfaction disorders; Original Research; Patients; Plasma; platelet‐rich plasma; postviral; Smell; smell loss; Steroids; United States > US; Pennsylvania; postviral; smell loss; olfaction; platelet‐rich plasma; hyposmia
• ISSN: 2378-8038; 2378-8038
• DOI: 10.1002/lio2.357

Background Olfactory dysfunction is a prevalent problem with a significant impact on quality of life and increased mortality. Limited effective therapies exist. Platelet‐rich plasma (PRP) is an autologous biologic product with anti‐inflammatory and neuroprotective effects. This novel pilot study evaluated the role of PRP on olfactory neuroregeneration in patients with hyposmia. Methods Seven patients who had olfactory loss greater than 6 months in duration, no evidence of sinonasal inflammatory disease, and no improvement with olfactory training and budesonide topical rinses were enrolled in this preliminary study. Patients received a single intranasal injection of PRP into the mucosa of the olfactory cleft. The Sniffin' Sticks olfactory test consisting of threshold, discrimination, and identification measurements (TDI) was administered at the beginning of the study and at 1 and 3 months. Results All patients reported a subjective improvement of their smell shortly after injection but then stabilized. At 3‐month post‐treatment, two patients with functional anosmia (TDI < 16) did not improve significantly. Five patients with hyposmia (TDI > 16 but <30) showed an improvement with 60% achieving normosmia (TDI > 30) at 3‐month follow‐up. On average, patients with baseline TDI > 16 improved by 5.85 points with the most significant improvement in the threshold subcomponent. There were no adverse outcomes from intranasal PRP injections. Conclusion PRP appears safe for use in the treatment of olfactory loss, and preliminary data suggest possible efficacy, especially for those with moderate yet persistent loss. Further studies will help determine optimal frequency and duration of use. Level of evidence: 2B